Cytotoxic activity, tumor accumulation, and tissue distribution of ruthenium-103-labeled bleomycin.
Bleomycin (BLM) was labeled with gamma-emitting 103Ru. Yields of 103Ru-labeled BLM as high as 50.6% were attained. 103Ru-labeled BLM was stable in vitro and the 103ru label was not displaced by large excesses of Cu (II) and Co (II) or Fe (III). Chromatography of the urine following 103Ru-labeled BLM injection indicated no in vivo decomposition. Pharmacokinetic studies in healthy inbred SD and tumor-bearing inbred BUF rats demonstrated tumor accumulations, tissue distributions, and clearance nearly identical with those reported for 3H-labeled BLM. Cytotoxicity studies on a WI-L2 human B-cell line showed that BLM labeled with nonradioactive Ru retained 100% of the activity demonstrated by native BLM. Thus BLM may be labeled with isotopes of Ru to form stable complexes by a simple, rapid reaction without loss of its chemotherapeutic properties or variations in its in vivo distribution. BLM labeled with the proper Ru isotope should prove useful as a gamma-emitting tracer for BLM or a beta-emitting compound capable of providing combination chemotherapy and radiotherapy of tumors.
D000818:Animals; D001761:Bleomycin / Q000378:metabolism* / Q000627:therapeutic use; D055598:Chemical Phenomena; D002621:Chemistry; D004583:Electrons / Q000627:therapeutic use; D007553:Isotope Labeling; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy* / Q000378:metabolism; D011839:Radiation, Ionizing / Q000627:therapeutic use; D011868:Radioisotopes; D011877:Radionuclide Imaging / Q000379:methods; D051381:Rats; D011919:Rats, Inbred Strains; D012428:Ruthenium; D014018:Tissue Distribution
D011868:Radioisotopes; D001761:Bleomycin; D012428:Ruthenium